Autoimmune Disease Therapeutics Market
Therapeutics are the New Elixir to Cure Autoimmune Diseases. Unveil more Insights with FMI's Analysis
Autoimmune Disease Therapeutics Market by Drug Class, Indication, Sales Channel & region - Forecast 2022 - 2032
Autoimmune Disease Therapeutics Market Outlook (2022-2032)
[308 Pages Report] The global autoimmune disease therapeutics market is likely to be valued at US$ 68,410.54 million in 2022 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of US$ 1,17,967.44 million by 2032.A historical CAGR of 4.8% has been recorded during the analysis by Future Market Insights.
It is identified that there are more than 80 different types of autoimmune disorders amongst which multiple sclerosis, IBS, lupus, type 1 diabetes, psoriasis, rheumatoid arthritis, and others are the most common forms of autoimmune diseases.
|
Report Attribute |
Details |
|
Autoimmune Disease Therapeutics Market Value (2022) |
US$ 68,410.54 Million |
|
Autoimmune Disease Therapeutics Market Anticipated Value (2032) |
US$ 1,17,967.44 Million |
|
Autoimmune Disease Therapeutics Management Projected Growth Rate (2022-2032) |
5.6% |
The adoption of autoimmune disease therapeutics insights reveals they are being used as these diseases cause abnormally low activity or overactivity of the immune systems, attacking the body’s own tissues and cells, which need to be treated therapeutically.
It is witnessed that autoimmune diseases decrease the body’s ability to fight foreign agents, and it is more common in women than in men. Therefore, it is anticipated that the autoimmune disease therapeutics market is likely to have significant growth during the forecast period.
Let us know your requirement to get
100% FREE customization
Prime Factors Driving And Deterring The Market Growth Of Autoimmune Disease Therapeutics
The global market for autoimmune disease therapeutics is expected to have increased growth in the coming years and there are many factors identified that are likely to bolster the market dynamics in a positive direction.
Besides the propelling factors, a number of challenges are also identified. Let us take an in-depth look at the following drivers and restraints.
DRIVERS:
|
|
|
|
RESTRAINTS:
|
|
|
Regional Outlook
How is North American Autoimmune Disease Therapeutics Market Performing?
North America is projected to dominate the global autoimmune disease therapeutics market during the forecast period. Currently, the region is accountable for 38.0% of the total market share of autoimmune disease therapeutics.
The growth in the North American region can be attributed to:
- Growing prevalence of various forms of autoimmune disorders in the region.
- Government initiatives such as the Affordable Care Act and Patient Protection Act are further fueling the growth of the market size of autoimmune disease therapeutics.
- Increasing healthcare expenditure in this region is also expected to drive the overall autoimmune disease therapeutics market in North America.
Growth Outlook of Europe Autoimmune Disease Therapeutics Market
Europe is projected to have a slow-paced growth during the forecast period, yet it will hold a significant share of the market. At present, the European region is accountable for 18.0% of the total market share of autoimmune disease therapeutics.
The growth can be attributed to:
- Increased penetration of new technologies such as potable diagnostic equipment and novel biomarkers are contributing largely to the market growth of Europe.
- A large number of lucrative growth opportunities and improving healthcare infrastructure are likely to foster growth in Europe.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystStart-Up Ecosystem
The start-up companies in the autoimmune disease therapeutics market are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop effective therapeutic solutions for the end-users.
Three Start-Ups Gaining Traction in The Market
Viela Bio – The US-based start-up creates a novel therapeutic to treat neuromyelitis optica spectrum disorder, a neuroinflammatory disorder that causes irreversible blindness and paralysis. UPLIZNA targets the aquaporin-4 antibody in adult patients. A combination of immunosuppressive therapies with UPLIZNA helps patients overcome this rare disease with minimal side effects, including urinary tract infection and influenza.
Immundnz – This Bristish start-up develops COMPIT, an in vitro immune response platform to understand responses in autoimmune disorders. The platform is versatile and helps analyze various parameters including cell viability and cytotoxicity. COMPIT consists of a variety of immune and protein assays that are customizable according to any experimental model to study drug immunology or immune safety.
Landos Biopharma – The Swedish start-up is working on novel therapeutic drugs to treat gastrointestinal immune disorders. The start-up’s lead candidate BT-11, an oral therapeutic drug for treating ulcerative colitis, is currently undergoing Phase II clinical trials. BT-11 activates the lanthionine synthetase C-like protein 2 (LANCL2) pathway, which plays a pivotal role in metabolism and immune response.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Competitive Landscape
Key Market Players Revolutionizing the Autoimmune Disease Therapeutics Market
The market players are focusing on organic growth strategies such as product launches, product approvals, and other such patents and events. They are anticipated to have lucrative growth opportunities in the future with rising demand for autoimmune disease drugs in the global market.
Recent Developments
- Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that is targeting the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer.
- ImmuneID is a precision immunology company that is using its genome-wide, high-throughput platform to provide a comprehensive understanding of individual immune responses. They are developing targeted immunological-based biologics using a unique oral delivery platform.
Key companies identified are
- Abbott Laboratories
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- UCB S.A.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.6% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments In The Autoimmune Disease Therapeutics Market
By Drug Class Type:
- Anti-inflammatory
- Antihyperglycemics
- NSAIDs
- Interferons
- Others
By Indication:
- Rheumatic Disease
- Type 1 Diabetes
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Other Indications
By Sales Channel:
- Hospital Pharmacy
- Drug Store & Retail Pharmacy
- Online Store
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
The growth outlook for the autoimmune disease therapeutics market is predicted to advance at a CAGR of 5.6% from 2022 to 2032.
The North American region is anticipated to lead the autoimmune disease therapeutics market during the forecast period.
The autoimmune disease therapeutics market is likely to hold a valuation of US$ 1,17,967.44 million by 2032.
The healthcare sector is the key driver in the autoimmune disease therapeutics market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Immunosuppressant’s
5.3.2. Anti-Inflammatory Drugs
5.3.3. Corticosteroids
5.3.4. Nonsteroidal Anti-inflammatory Drugs
5.3.5. Biologics
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Drug Stores
6.3.4. Independent Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. India
11.2.1.5. Malaysia
11.2.1.6. Singapore
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of APAC
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Drug Class
13.1.2.2. By Distribution Channel
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Drug Class
13.2.2.2. By Distribution Channel
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Drug Class
13.3.2.2. By Distribution Channel
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Drug Class
13.4.2.2. By Distribution Channel
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Drug Class
13.5.2.2. By Distribution Channel
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Drug Class
13.6.2.2. By Distribution Channel
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Drug Class
13.7.2.2. By Distribution Channel
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Drug Class
13.8.2.2. By Distribution Channel
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Drug Class
13.9.2.2. By Distribution Channel
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Drug Class
13.10.2.2. By Distribution Channel
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Drug Class
13.11.2.2. By Distribution Channel
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Drug Class
13.12.2.2. By Distribution Channel
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Drug Class
13.13.2.2. By Distribution Channel
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Drug Class
13.14.2.2. By Distribution Channel
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Drug Class
13.15.2.2. By Distribution Channel
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Drug Class
13.16.2.2. By Distribution Channel
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Drug Class
13.17.2.2. By Distribution Channel
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Drug Class
13.18.2.2. By Distribution Channel
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Drug Class
13.19.2.2. By Distribution Channel
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Drug Class
14.3.3. By Distribution Channel
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Abbott Laboratories
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Amgen Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Genentech Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. F. Hoffmann-La Roche AG
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Merck & Co. Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Bayer Schering Pharma AG
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Johnson & Johnson Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Biogen Idec Inc.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. GlaxoSmithKline Plc
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Squibb Company
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Elan Corporation Plc
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.12. Eli Lilly and Company
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
15.1.13. Chugai Pharmaceutical Co. Ltd.
15.1.13.1. Overview
15.1.13.2. Product Portfolio
15.1.13.3. Profitability by Market Segments
15.1.13.4. Sales Footprint
15.1.13.5. Strategy Overview
15.1.13.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 02: Global Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 03: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 04: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 05: North America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 06: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 07: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 08: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 09: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 12: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: MEA Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 18: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 02: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 03: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 04: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 05: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 06: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 07: Global Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 08: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 09: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 10: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 13: Global Market Attractiveness by Drug Class, 2022-2032
Figure 14: Global Market Attractiveness by Distribution Channel, 2022-2032
Figure 15: Global Market Attractiveness by Region, 2022-2032
Figure 16: North America Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 17: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 28: North America Market Attractiveness by Drug Class, 2022-2032
Figure 29: North America Market Attractiveness by Distribution Channel, 2022-2032
Figure 30: North America Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 32: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 40: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 43: Latin America Market Attractiveness by Drug Class, 2022-2032
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2022-2032
Figure 45: Latin America Market Attractiveness by Country, 2022-2032
Figure 46: Europe Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 47: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 55: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 58: Europe Market Attractiveness by Drug Class, 2022-2032
Figure 59: Europe Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Europe Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 62: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 73: Asia Pacific Market Attractiveness by Drug Class, 2022-2032
Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2022-2032
Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 76: MEA Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 77: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: MEA Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 83: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 85: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 86: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 88: MEA Market Attractiveness by Drug Class, 2022-2032
Figure 89: MEA Market Attractiveness by Distribution Channel, 2022-2032
Figure 90: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
